← Back to Search

Wakefulness-Promoting Drug

Soliramfetol for Glioblastoma (JAZZ Trial)

Phase 2
Waitlist Available
Led By Roy Strowd, MD
Research Sponsored by Wake Forest University Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 50-65 minutes at baseline and approximately 70 days post treatment
Awards & highlights

Summary

This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug. Giving solriamfetol may improve sleep, memory, fatigue, mood, or quality of life in patients with brain tumors (gliomas).

Eligible Conditions
  • Glioblastoma
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~50-65 minutes at baseline and approximately 70 days post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 50-65 minutes at baseline and approximately 70 days post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of Adverse Events
Secondary outcome measures
7 day Actigraphy
7-day Patient-Reported Sleep Diary
Beck's Depression Inventory (BDI)
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: SolriamfetolExperimental Treatment1 Intervention
Given orally daily

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor
1,253 Previous Clinical Trials
1,010,896 Total Patients Enrolled
10 Trials studying Glioblastoma
346 Patients Enrolled for Glioblastoma
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,959,365 Total Patients Enrolled
324 Trials studying Glioblastoma
23,152 Patients Enrolled for Glioblastoma
Roy Strowd, MDPrincipal InvestigatorWake Forest University Health Sciences
6 Previous Clinical Trials
98 Total Patients Enrolled
1 Trials studying Glioblastoma
24 Patients Enrolled for Glioblastoma
~6 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top